InvestorsObserver is giving Entasis Therapeutics Holdings Inc (ETTX) an Analyst Rating Rank of 79, meaning ETTX is ranked higher by analysts than 79% of stocks. The average projection by analysts for ETTX is $6.25 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Entasis Therapeutics Holdings Inc Stock Today?
Entasis Therapeutics Holdings Inc (ETTX) stock has risen 5.53% while the S&P 500 is lower by -0.45% as of 2:05 PM on Friday, Jan 15. ETTX has gained $0.14 from the previous closing price of $2.53 on volume of 589,525 shares. Over the past year the S&P 500 has risen 13.92% while ETTX is lower by -44.03%. ETTX lost -$3.36 per share the over the last 12 months.
Click Here to get the full report on Entasis Therapeutics Holdings Inc (ETTX) Stock.